Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus
Public ClinicalTrials.gov record NCT00502242. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Placebo Controlled, Double-Blind Comparative Study Evaluating The Effect of Ramipril On Urinary Protein Excretion In Maintenance Renal Transplant Patients Converted To Sirolimus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to determine the efficacy of ramipril in preventing a urinary protein to creatinine ratio (U p/c) greater than 0.5 following conversion to sirolimus from a calcineurin inhibitor (CNI) in maintenance kidney transplant patients.
Study identification
- NCT ID
- NCT00502242
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 229 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2007
- Primary completion
- Aug 31, 2013
- Completion
- Aug 31, 2013
- Last update posted
- Aug 26, 2014
2007 – 2013
United States locations
- U.S. sites
- 24
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Los Angeles | California | 90033-4612 | — |
| Pfizer Investigational Site | Los Angeles | California | 90033 | — |
| Pfizer Investigational Site | San Francisco | California | 94115 | — |
| Pfizer Investigational Site | Aurora | Colorado | 80045 | — |
| Pfizer Investigational Site | Denver | Colorado | 80218 | — |
| Pfizer Investigational Site | Gainesville | Florida | 32610 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60637 | — |
| Pfizer Investigational Site | Iowa City | Iowa | 52242 | — |
| Pfizer Investigational Site | Lexington | Kentucky | 40536-0293 | — |
| Pfizer Investigational Site | Portland | Maine | 04102 | — |
| Pfizer Investigational Site | Boston | Massachusetts | 02215 | — |
| Pfizer Investigational Site | Springfield | Massachusetts | 01107 | — |
| Pfizer Investigational Site | Springfield | Massachusetts | 01199 | — |
| Pfizer Investigational Site | Gosse Pointe | Michigan | 48236 | — |
| Pfizer Investigational Site | Buffalo | New York | 14215 | — |
| Pfizer Investigational Site | Valhalla | New York | 10595 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44106 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44195 | — |
| Pfizer Investigational Site | Harrisburg | Pennsylvania | 17104 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19102-1192 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19102 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| Pfizer Investigational Site | Providence | Rhode Island | 02903 | — |
| Pfizer Investigational Site | Charleston | South Carolina | 29425-6290 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 25 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00502242, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 26, 2014 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00502242 live on ClinicalTrials.gov.